McKesson Corporation

Healthcare · Medical - Distribution

Overall research band Above average

Quality Above average

Valuation Weak

Balance sheet Strong

Market confirmation Exceptional

One-minute company read

What this report can tell you now

What the company does

McKesson Corporation is a global provider of healthcare services, organized into four main business segments. The U.S. Pharmaceutical division distributes branded, generic, specialty, biosimilar, and over-the-counter medications, and offers support services such as practice management, technology solutions, and consulting to pharmacies and specialty medical practices. Internationally, McKesson delivers distribution and support services to wholesale, institutional, and retail clients in 13 European countries and Canada. Its Medical-Surgical Solutions unit supplies medical-surgical products and logistics management to healthcare providers. The Prescription Technology Solutions segment partners with biopharmaceutical and life sciences companies to improve medication access and adherence, connecting pharmacies, providers, payers, and biopharma through technology and logistics services. McKesson generates revenue primarily through the distribution of healthcare products and the provision of related services.

The current research profile is Deep Value, with weak market confirmation. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Recent market behavior is the strongest visible confirmation. Check whether it agrees with the underlying business evidence.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

Operating margin1.6%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years11.2%Model input; read with the evidence status and period context.

FCF margin1.4%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.